000 01338 a2200289 4500
005 20250516233525.0
264 0 _c20150710
008 201507s 0 0 eng d
022 _a1557-3265
024 7 _a10.1158/1078-0432.CCR-14-2306
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aPoliti, Katerina
245 0 0 _aPerfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
_h[electronic resource]
260 _bClinical cancer research : an official journal of the American Association for Cancer Research
_cNov 2014
300 _a5576-8 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Comment
650 0 4 _aCarbazoles
_xpharmacology
650 0 4 _aDrug Resistance, Neoplasm
_xgenetics
650 0 4 _aHumans
650 0 4 _aMutation
650 0 4 _aPiperidines
_xpharmacology
650 0 4 _aProtein Kinase Inhibitors
_xpharmacology
650 0 4 _aReceptor Protein-Tyrosine Kinases
_xantagonists & inhibitors
700 1 _aGettinger, Scott
773 0 _tClinical cancer research : an official journal of the American Association for Cancer Research
_gvol. 20
_gno. 22
_gp. 5576-8
856 4 0 _uhttps://doi.org/10.1158/1078-0432.CCR-14-2306
_zAvailable from publisher's website
999 _c24197502
_d24197502